Use of peripheral blood CD4/CD8 ratio to predict therapy-induced durable complete response. Background: Activation of the EGFR signaling can lead to the activation of MAPK, PI3K/AKT, the STAT pathway ...
The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...
NEW YORK, March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the activation of Washington University School of Medicine ...
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical ...
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has ...
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now discovered a molecular-level resistance mechanism that begins to take hold as ...
"We are pleased to have selected our initial clinical sites," said Robb Knie, the Company's CEO. "The caliber of the clinics selected represents some of the best cancer treatment facilities in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback